Merck & Co., Inc. (NYSE: MRK) has announced an unusually early access strategy for alimatravir, its investigational once-monthly oral pre-exposure prophylaxis candidate for HIV-1 prevention. The company has signed seven non-exclusive, royalty-free voluntary licensing agreements covering 129 low- and middle-income countries, while also preparing regional manufacturing and initial Merck-supplied inventory, although the drug remains in Phase 3 development and has not been approved by any regulator.
The timing makes the announcement more strategically significant than a conventional post-approval licensing programme. Merck is asking generic manufacturers, public health agencies and procurement organisations to begin preparing for a product whose prevention efficacy has not yet been established, effectively moving access planning ahead of the clinical and regulatory verdict. That could shorten the interval between a future approval and broad availability, but it also places considerable weight on two recruiting Phase 3 trials that are not expected to complete their primary analyses until 2027.
The public health rationale is substantial. UNAIDS estimates that approximately 1.2 million people acquired HIV during 2025, while the new global strategy calls for 20 million people to have access to antiretroviral-based HIV prevention options by 2030. Merck’s access architecture therefore addresses a real implementation problem, but the eventual contribution of alimatravir will depend on efficacy, safety, price, reliable supply, regulatory coordination and whether people prefer a monthly pill to the increasingly varied PrEP options already available.
Why is Merck licensing alimatravir before Phase 3 efficacy has been established?
Merck’s seven licences cover both public and private-sector supply and include three manufacturers in sub-Saharan Africa and four based in India. The participating companies are Aspen Pharmacare Holdings Limited, Quality Chemical Industries Limited, UCL Kenya, Aurobindo Pharma Limited, Cipla Limited, Emcure Pharmaceuticals Limited and Viatris Inc. Merck said the agreements would allow the companies to begin development and regulatory work for generic alimatravir before the pivotal trials are complete.
That sequencing matters because generic introduction is not as simple as granting patent rights after approval. Manufacturers may need technology transfer, formulation development, analytical comparability work, validation batches, quality-system preparation, regulatory submissions and inspections before they can supply national programmes. Beginning those activities early could remove years from the traditional access timeline, particularly when multiple countries rely on separate registrations, procurement mechanisms or international quality-assurance pathways.
The approach also spreads execution risk. If alimatravir succeeds clinically, Merck will not be solely responsible for creating manufacturing capacity for dozens of high-burden markets after launch. If the trials fail, however, licensees may have committed technical resources to a product that never reaches commercialisation. The agreements therefore represent advance industrial planning rather than evidence that the candidate will become an approved or widely used prevention medicine.
What must EXPrESSIVE-10 and EXPrESSIVE-11 prove about once-monthly oral PrEP?
Alimatravir is being tested in two randomised, active-controlled, double-blind Phase 3 studies using daily oral emtricitabine and tenofovir disoproxil fumarate as the active comparator. EXPrESSIVE-10 is expected to enrol about 4,580 women and adolescent girls in Kenya, South Africa and Uganda, while EXPrESSIVE-11 is targeting approximately 4,390 participants across 16 countries. Together, the studies could generate an evidence base of almost 9,000 participants.
EXPrESSIVE-10 is designed to assess whether monthly alimatravir prevents sexually acquired HIV-1 more effectively than daily oral PrEP in its enrolled population. EXPrESSIVE-11 is examining whether the monthly regimen performs as well as or better than the daily comparator across a geographically and demographically broader population. The registry lists estimated primary completion in July 2027 for EXPrESSIVE-11 and October 2027 for EXPrESSIVE-10, although trial timelines can change.
These are demanding studies because existing oral PrEP is highly effective when taken consistently. The clinical question is therefore not simply whether alimatravir has antiviral activity. Merck must demonstrate that its pharmacology and monthly dosing schedule translate into protection under real trial conditions, while producing a safety profile suitable for repeated preventive use among people who do not have HIV.
Adherence will be central to interpretation. A monthly tablet could reduce the number of required doses from 365 to 12 each year, but less frequent dosing does not automatically eliminate missed doses. Investigators and regulators will need to understand how much protection remains when a dose is delayed, how quickly protection begins after dosing, and what testing or alternative prevention measures would be required around interruptions.
How much confidence does the existing alimatravir safety evidence actually provide?
The Phase 3 programme was supported by a completed double-blind Phase 2 study involving 350 adults considered to have a low likelihood of HIV exposure. Participants received 3 mg, 6 mg or 12 mg of alimatravir, or placebo, once monthly for six months. Reported adverse-event rates were similar across the active and placebo groups, while no clinically meaningful changes were identified in laboratory measures including total lymphocyte and CD4 T-cell counts.
Approximately 94% of participants received all six scheduled doses, and the pharmacokinetic profile of alimatravir and its active intracellular triphosphate supported further investigation of monthly administration. Earlier Phase 1 studies also showed a prolonged intracellular half-life, which provides the biological basis for infrequent dosing.
Those results are encouraging but limited. The Phase 2 study was primarily a safety and pharmacokinetic evaluation in participants with low HIV exposure risk. It was not designed to demonstrate prevention efficacy, determine how the medicine performs during exposure to HIV, or fully characterise uncommon adverse events across large and diverse populations.
Merck has said alimatravir is predicted to provide protection beginning within one hour of dosing. That remains a company-described prediction derived from pharmacology rather than a clinically established prevention claim. The Phase 3 programme must determine whether the candidate’s drug concentrations translate into consistent protection and whether safety findings remain acceptable with broader use and longer follow-up.
Can a monthly pill occupy the space between daily PrEP and long-acting injections?
The HIV prevention market now offers substantially more choice than it did when daily oral PrEP first became available. Established options include daily oral emtricitabine-based regimens and long-acting cabotegravir administered by intramuscular injection every two months. Gilead Sciences, Inc. has also secured United States approval for twice-yearly injectable lenacapavir, marketed as Yeztugo, while the World Health Organization recommends twice-yearly lenacapavir as an additional prevention choice within combination HIV prevention programmes.
Alimatravir could occupy a distinct position if successful. It would offer substantially fewer doses than a daily pill without requiring injections, clinic-administered dosing or the management of injection-site reactions. This could appeal to people who prefer oral medicines but struggle with daily adherence, as well as health systems where regular injection appointments are difficult to sustain.
Competition is still moving quickly. Gilead has obtained United States Food and Drug Administration acceptance of an application for a once-weekly oral formulation of lenacapavir, with a target action date of February 2, 2027. Alimatravir could therefore enter a market containing daily tablets, weekly oral therapy, two-monthly injections and twice-yearly injections, depending on future regulatory outcomes.
There is unlikely to be one universally preferred format. Some people may favour the discretion and familiarity of tablets. Others may prefer injections that remove responsibility for remembering doses between appointments. The commercial and public health value of alimatravir will depend less on claiming one schedule is inherently superior and more on whether monthly oral dosing expands effective, persistent use among people not adequately served by existing choices.
Will royalty-free licences translate into affordable and dependable supply at scale?
Royalty-free licensing removes one potential cost layer, but it does not by itself establish an affordable final price. Manufacturing costs, quality assurance, packaging, distribution, regulatory fees, country taxes, procurement volumes and financing conditions will influence what national programmes and private purchasers ultimately pay. Merck has not announced a target price, procurement commitment or guaranteed launch volume for generic alimatravir.
The inclusion of African manufacturers from the initial licensing stage is nevertheless important. Merck said it was the first time manufacturers in sub-Saharan Africa had been included in the initial voluntary licences for an HIV prevention product. Regional production could improve supply resilience and reduce dependence on a narrow group of distant manufacturing centres, although those benefits will require successful technology transfer, internationally recognised quality standards and commercially sustainable demand.
Merck is also holding discussions with organisations including Fundação Oswaldo Cruz, or Fiocruz, to support availability in Latin America. The company plans to manufacture initial supply itself and continue supplying the product while generic licensees complete development, obtain regulatory clearances and establish production. This bridging model could reduce early shortages, but planned capacity should not be mistaken for validated commercial supply.
Financing may become as important as manufacturing. The global HIV response entered 2026 under pressure from reductions and uncertainty in international funding, while UNAIDS has emphasised the need for more country-led and domestically financed prevention programmes. Even a competitively priced monthly tablet will require funded demand, community distribution, testing services, healthcare training and reliable procurement forecasts before manufacturing scale can translate into sustained use.
What does the access plan signal about Merck’s HIV strategy and market sentiment?
Alimatravir forms part of a wider Merck HIV portfolio spanning daily, weekly and monthly dosing concepts across treatment and prevention. The company is developing weekly oral combinations involving islatravir and pursuing monthly alimatravir for PrEP, positioning dosing convenience as a central element of its future HIV strategy.
For investors, the access announcement is better understood as a long-term pipeline and execution signal than an immediate revenue catalyst. Alimatravir still faces Phase 3 readouts, regulatory review, manufacturing scale-up and market introduction. Royalty-free generic licensing in 129 countries may also limit direct per-patient economics in those markets, although broader access could support volume, public health credibility and adoption across a large geographical footprint.
Merck shares closed at $130.48 on July 23, 2026, after rising 2.36% during the session. The stock was about 2.3% higher over five trading sessions and approximately 8.2% above its June 24 close, while trading close to its 52-week high of $131.74. The price movement coincided with the announcement period, but the available evidence does not establish that the alimatravir access plan caused the gain.
The market’s eventual assessment will depend on efficacy data rather than the access framework alone. Positive Phase 3 results could establish alimatravir as a differentiated oral prevention candidate in a strategically important market. Weak efficacy, unexpected safety findings or difficulty demonstrating an advantage over well-used daily PrEP would reduce the value of even the most ambitious licensing network.
Which milestones will decide whether early access planning improves real-world prevention?
The first decisive milestones will come from EXPrESSIVE-10 and EXPrESSIVE-11. Attention will centre on incident HIV infections, performance against daily emtricitabine and tenofovir disoproxil fumarate, adherence, discontinuations, laboratory findings, resistance observations and whether protection remains consistent across populations and geographies.
Regulatory agencies will also need sufficient evidence to define the eligible population, dosing instructions, HIV testing requirements, missed-dose management and any restrictions involving pregnancy, adolescence, renal function or concomitant medicines. Approval in the United States or another stringent regulatory jurisdiction would not automatically authorise supply across the 129 licensed countries.
The access strategy will then face its own measurable tests. Generic manufacturers must complete development, achieve quality and regulatory milestones, validate commercial-scale production and offer prices that national programmes can afford. Merck and its partners will need to convert licensing rights into approved products, funded purchase orders and dependable delivery.
Merck has moved earlier than the traditional pharmaceutical access model normally allows. That could prove consequential if alimatravir succeeds, because manufacturing and regulatory preparation would already be underway when the clinical verdict arrives. For now, however, the company has accelerated the route to potential availability, not the evidence required to reach it.
